Komori
Kidswell Bio (4584) · InitiativeAdvanced

Strengthening Corporate Governance and Internal Management Systems

First written in FY2016. 6 of 14 entries say "Advanced", first in FY2017. Latest entry: 2026-05-14.

14entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2018-Q3 – FY2018Cited as achievedFY2023-Q1 – FY2023-Q32016: 320162017: 120172018: 220182019: 120192020: 120202021: 120212022: 220222023: 120232024: 020242025: 120252026: 1
Same theme, other companies
Continuous Strengthening of Corporate Governance and Internal Control SystemsA theme 968 companies write about · 4 as a headwind · 1068 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 185 companies compared. The sentences above are computed from all 185.Comparing 200 of the theme's 1074 threads.
Full recordFilings, disclosures and news, newest first
  1. 2026-05-14AdvancedEarnings presentation

    「The organizational structure was reviewed in line with business progress. Organizational reforms are under way to improve resource utilization and strengthen coordination.」

    The company is reviewing its organizational structure in line with business progress and pursuing organizational reforms to use resources more effectively.
  2. FY2025AdvancedAnnual report

    「The company’s internal audits are conducted for each department by the internal audit department, which reports directly to the Representative Director and President, with a structure comprising 2 internal audit staff members.」

    The company discloses specific management arrangements, including 2 internal audit staff members, oversight by 2 outside directors and 2 outside corporate auditors, and the assignment of corporate auditors to S-Quatre and internal audits.
  3. FY2023-Q3Cited as achievedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the company underwent a quarterly review by 南青山監査法人 of its quarterly financial statements for the third-quarter accounting period (1 October 2022 to 31 December 2022) and the cumulative third-quarter period (1 April 2022 to 31 December 2022).」

    The company reiterates that it underwent a quarterly review by 南青山監査法人 after the change in audit firms.
  4. FY2023-Q1Cited as achievedAnnual report

    「First-quarter accounting period and cumulative first-quarter period of the 23rd fiscal year   南青山監査法人」

    The company reiterates that it underwent a first-quarter review by 南青山監査法人 after the change in audit firms.
  5. FY2022AdvancedAnnual report

    「The term of office of KPMG AZSA LLC, the company’s accounting auditor, will expire upon the conclusion of the 22nd Annual General Meeting of Shareholders held on 27 June 2022. Although the current accounting auditor has an adequate system to ensure that audits are conducted appropriately and properly, the company determined that 南青山監査法人 was an appropriate new candidate after comparing it with other audit firms, because the current auditor had audited the company for an extended period, making it an appropriate time to obtain a fresh perspective, and because the company considered audit services suited to its business scale and the appropriateness of audit fees.」

    The company presents a specific change in its governance and audit structure, with the audit firm changing from KPMG AZSA LLC to 南青山監査法人.
  6. FY2021AdvancedAnnual report

    「The company has adopted a company-with-a-board-of-corporate-auditors structure. It has also introduced an executive officer system to separate management oversight from execution and thereby strengthen and improve the efficiency of the Board of Directors.」

    The company describes specific arrangements under its policy of strengthening corporate governance, including an executive officer system that separates oversight from execution within a company-with-a-board-of-corporate-auditors structure.
  7. FY2020RestatedAnnual report

    「In accordance with its risk management regulations, the company analyzes risks and considers response measures, while also preparing for emergencies if risks materialize by establishing emergency response procedures.」

    The company reconfirms its internal management and governance systems, including risk management regulations, emergency response measures, internal audits and audits of subsidiaries.
  8. FY2019AdvancedAnnual report

    「In addition, subsidiaries are subject to regular internal audits by the company’s internal audit department, and the audit results are reported to the company’s Representative Director and President.」

    Following the full consolidation of セルテクノロジー, the company describes specific management arrangements under which subsidiaries are subject to regular internal audits.
  9. FY2018RestatedAnnual report

    「The company’s internal audits are conducted for each department by the Internal Audit Office, which reports directly to the Representative Director and President, with a structure comprising 1 head of the Internal Audit Office and 1 staff member.」

    The company reconfirms its governance and internal management systems, comprising the Internal Audit Office, board of corporate auditors, internal control reporting and risk management regulations.
  10. FY2018-Q3RestatedAnnual report

    「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」

    The company has disclosed that there have been no material changes in existing risks related to its internal management systems and governance.
  11. FY2017AdvancedAnnual report

    「The company’s internal audits are conducted for each department by the Internal Audit Office, which reports directly to the Representative Director and President, with a structure comprising 1 head of the Internal Audit Office and 1 staff member.」

    In addition to its existing policy of strengthening internal management systems, the company describes specific governance arrangements, including an Internal Audit Office reporting directly to the president, a board of corporate auditors and an internal control reporting system.
  12. FY2017-Q2RestatedAnnual report

    「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」

    The company has disclosed that no new risks have arisen and no material changes have occurred in existing risks related to its internal management systems and governance.
  13. FY2017-Q1RestatedAnnual report

    「During the three months ended March, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」

    The company has disclosed that there have been no material changes in existing risks related to its internal management systems and governance.
  14. FY2016First statedAnnual report

    「Although the company is a small organization, it will work to strengthen its internal management systems to earn sufficient trust. It will also establish corporate governance and enhance management transparency so that it can respond systematically and appropriately to the needs of all stakeholders.」

    The company places importance on the social credibility, internal controls and compliance that support its external networks and transactions with listed companies and public research institutions.
Moved together

"Enhancing Development Capabilities and Speed Through Partnerships with Contract Research Organizations and Pharmaceutical Companies" moved the same way as this thread, in the same document, in 4 of its 14 moves.

432222★123456
  1. ★This thread
  2. 1Enhancing Development Capabilities and Speed Through Partnerships with Contract Research Organizations and Pharmaceutical Companies4×
  3. 2Early Profitability and Strengthening the Financial Condition3×
  4. 3Securing a Competitive Product Advantage through Active Pharmaceutical Ingredient Quality, Manufacturing Costs, and Usability2×
  5. 4Global Entry into the Biosimilars Business2×
  6. 5Four-party joint research on a treatment for cerebral palsy using dental pulp stem cells2×
  7. 6Joint commercialization with Mochida Pharmaceutical of a dental pulp stem cell-based treatment for intestinal ganglion cell paucity2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Kidswell Bio yet. It last moved in the Earnings presentation of 2026-05-14: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Strengthening Corporate Governance and Internal Management Systems | Kidswell Bio Corporation (4584) | Komori